Whether you already hold one of these financial giants or are considering adding a bank to your portfolio, this will help you understand key strengths, weaknesses, and long-term investment potential.
Energy Transfer showcases potential for investors through its record financial achievements, distribution yield, and strategic diversification efforts.
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78 million.
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.
Retailers and consumer-facing companies are reeling more prominently as they fear the potential hike to consumer prices of their products will directly hurt sales.
RBC Capital Markets analyst maintains BlackBerry with Sector Perform rating, lowers price target to $3.75 due to lower revenue and EBITDA guidance for fiscal 2026.
The brokerage highlighted that the outlook for residential demand for Enphase’s products remains challenged due to worsening sentiment with respect to the Inflation Reduction Act.
April 2, 2025 – Tesla, Inc. (NQ:TSLA) shares fell sharply in morning trading today after the electric vehicle giant reported first-quarter vehicle deliveries that significantly undershot Wall Street expectations. At 11:14:02 AM EDT, Tesla’s stock price stood at $265.62, reflecting a decline of $2.84, or
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.
Earlier, analysts at RBC Capital noted that while Enphase has a strong opportunity to return to growth eventually, in the near term, the company continues to cede market share amid softening demand.
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT)
fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price target by nearly 50% to $87. The downgrade was driven by weaker-than-anticipated feedback from physicians regarding ELEVIDYS, suggesting that market reception for the treatment had fallen short. Notably, ELEVIDYS had been a big piece of Sarepta's growth story as it contributed more than 50% of sales in the Q4'2024 quarter.
Fast-food chains are gaining investors’ and consumers' interest with innovative menu items, while the cruise company’s results showed holiday spending is strong.
Deutsche Bank expects the company’s first-quarter deliveries to be in the range of 340,000 to 350,000, much below the 386,810 deliveries reported in the corresponding quarter of 2024.
Paychex reported Q3 revenue of $1.509 billion, a 4.8% YoY increase, with EPS of $1.49 surpassing expectations. RBC analyst reiterated a Sector Perform rating on the shares of Paychex.
